Abstract
The NIBR (Novartis Institutes for BioMedical Research) compound collection enrichment and enhancement project integrates corporate internal combinatorial compound synthesis and external compound acquisition activities in order to build up a comprehensive screening collection for a modern drug discovery organization. The main purpose of the screening collection is to supply the Novartis drug discovery pipeline with hit-to-lead compounds for todays and the futures portfolio of drug discovery programs, and to provide tool compounds for the chemogenomics investigation of novel biological pathways and circuits. As such, it integrates designed focused and diversity-based compound sets from the synthetic and natural paradigms able to cope with druggable and currently deemed undruggable targets and molecular interaction modes. Herein, we will summarize together with new trends published in the literature, scientific challenges faced and key approaches taken at NIBR to match the chemical and biological spaces.
Current Topics in Medicinal Chemistry
Title: Key Aspects of the Novartis Compound Collection Enhancement Project for the Compilation of a Comprehensive Chemogenomics Drug Discovery Screening Collection
Volume: 5 Issue: 4
Author(s): Pascal Rigollier, Hans- Joerg Roth, Jurg Zimmermann, Karine Malagu, Jurgen Hinrichs, Rudolph Giger, David Orain, Peter Meier, Guido Koch, Friederike Stoll, Edgar Jacoby, Pierre Acklin, Jaroslav Stanek, Caroline Engeloch, Ulrich Schopfer, Benjamin Havill, Kamal Azzaoui, Maxim Popov and Ansgar Schuffenhauer
Affiliation:
Abstract: The NIBR (Novartis Institutes for BioMedical Research) compound collection enrichment and enhancement project integrates corporate internal combinatorial compound synthesis and external compound acquisition activities in order to build up a comprehensive screening collection for a modern drug discovery organization. The main purpose of the screening collection is to supply the Novartis drug discovery pipeline with hit-to-lead compounds for todays and the futures portfolio of drug discovery programs, and to provide tool compounds for the chemogenomics investigation of novel biological pathways and circuits. As such, it integrates designed focused and diversity-based compound sets from the synthetic and natural paradigms able to cope with druggable and currently deemed undruggable targets and molecular interaction modes. Herein, we will summarize together with new trends published in the literature, scientific challenges faced and key approaches taken at NIBR to match the chemical and biological spaces.
Export Options
About this article
Cite this article as:
Rigollier Pascal, Roth Joerg Hans-, Zimmermann Jurg, Malagu Karine, Hinrichs Jurgen, Giger Rudolph, Orain David, Meier Peter, Koch Guido, Stoll Friederike, Jacoby Edgar, Acklin Pierre, Stanek Jaroslav, Engeloch Caroline, Schopfer Ulrich, Havill Benjamin, Azzaoui Kamal, Popov Maxim and Schuffenhauer Ansgar, Key Aspects of the Novartis Compound Collection Enhancement Project for the Compilation of a Comprehensive Chemogenomics Drug Discovery Screening Collection, Current Topics in Medicinal Chemistry 2005; 5 (4) . https://dx.doi.org/10.2174/1568026053828376
DOI https://dx.doi.org/10.2174/1568026053828376 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ESR1, ESR2 and FSH Receptor Gene Polymorphisms in Combination: A Useful Genetic Tool for the Prediction of Poor Responders
Current Pharmaceutical Biotechnology Heterogeneous Catalysis in the Meerwein-Ponndorf-Verley Reduction of Carbonyl Compounds
Current Organic Chemistry Antimicrobial Agents Deriving from Indigenous Plants
Recent Patents on Food, Nutrition & Agriculture Chest CT Imaging in the Diagnosis of COVID-19: Rapid Publications are not Equal to Quality of Research
Current Medical Imaging The Role of CO-RADS Scoring System in the Diagnosis of COVID-19 Infection and its Correlation with Clinical Signs
Current Medical Imaging The Pharmacological Management of Intrahepatic Cholestasis of Pregnancy
Current Clinical Pharmacology Hybrid Molecules with Potential Activity Against Methicillin-resistance <i>Staphylococcus aureus</i>-Part II
Current Topics in Medicinal Chemistry Oligomerisation of Sarcoplasmic Reticulum Ca2+-ATPase Monomers from Skeletal Muscle
Protein & Peptide Letters Stabilization of Beta-Propeller Phytase by Introducing Xaa→Pro and Gly→Ala Substitutions at Consensus Positions
Protein & Peptide Letters Synthesis of Salinosporamide A and Its Analogs as 20S Proteasome Inhibitors and SAR Summarization
Current Topics in Medicinal Chemistry Imidazoles as Promising Scaffolds for Antibacterial Activity: A Review
Mini-Reviews in Medicinal Chemistry Role of Cyclic Tertiary Amine Bioactivation to Reactive Iminium Species: Structure Toxicity Relationship
Current Drug Metabolism Why has Cerium (III) Triflate been Forgotten Among the Catalysts for the Friedel-Crafts Acylation?
Letters in Organic Chemistry Computational Methods in the Discovery and Design of BACE-1 Inhibitors
Current Medicinal Chemistry The Role of Adipocytokines and Neurohormonal Dysregulation in Metabolic Syndrome
Current Diabetes Reviews Current Applications of Therapeutic Gases in Neonatal Intensive Care
Current Pediatric Reviews A Short Review on Important Drugs Under Clinical Trial Against COVID-19
Mini-Reviews in Medicinal Chemistry The Pharmacological Management of Delirium in Critical Illness
Current Drug Therapy Bioactivity of New μ and δ Opioid Peptides
Medicinal Chemistry A Decade of Targets and Patented Drugs for Chemotherapy of Chagas Disease
Recent Patents on Anti-Infective Drug Discovery